financetom
Business
financetom
/
Business
/
CI Financial Prices US$675.0 Million Private Offering of Notes
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CI Financial Prices US$675.0 Million Private Offering of Notes
May 22, 2024 2:16 PM

04:48 PM EDT, 05/22/2024 (MT Newswires) -- CI Financial ( CIXXF ) after trade Wednesday announced that it has successfully priced a private offering of US$675.0 million aggregate principal amount of its 7.500% notes due 2029.

A statement noted the Offering is expected to close on May 30, 2024, subject to satisfaction of customary closing conditions.

The wealth and asset-management company said it intends to use approximately US$645.0 million of the net proceeds from the Offering to finance the repurchase of any and all of its outstanding 4.100% Notes due 2051 in connection with the company's concurrent cash tender offer to purchase any and all of the 2051 Notes, and to pay related transaction fees and expenses, including up to an estimated US$40.0 million of potential cash tax expense payable in connection with the early retirement of the 2051 Notes, assuming the tender of all outstanding 2051 Notes in the Tender Offer.

CI added it intends to use the remaining proceeds from the offering for general corporate purposes, which may include repurchases and/or repayments of certain of its other existing indebtedness and potential future repurchases of its common shares. To the extent that the 2051 Notes are not purchased in the Tender Offer, CI intends to use the portion of the net proceeds intended to be used to retire 2051 Notes solely for other repurchases and/or repayments of its existing indebtedness.

CI Financial ( CIXXF ) shares closed down $0.02 to $14.70 on the Toronto Stock Exchange

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Banco Santander Hires DealMakers From Perella, William Blair, Moelis
Market Chatter: Banco Santander Hires DealMakers From Perella, William Blair, Moelis
Apr 10, 2024
03:07 PM EDT, 04/10/2024 (MT Newswires) -- Banco Santander (SAN) recently hired dealmakers from three rival investment banking firms in the US, Bloomberg reported Wednesday. Robert Losquadro from Perella Weinberg Partners has been appointed as head of specialty finance and lending technology, Michael Gebo from William Blair as head of insurance; and Paul Hwang from Moelis ( MC ) as...
US airlines seek FAA extension of New York minimum flight requirements cuts -letter
US airlines seek FAA extension of New York minimum flight requirements cuts -letter
Apr 10, 2024
WASHINGTON, April 10 (Reuters) - Major U.S. airlines are asking the Biden administration to extend cuts to minimum flight requirements at congested New York City-area airports through October 2025, citing air traffic controller shortages, according to a letter seen by Reuters. Under minimum flight requirements, airlines can lose their takeoff and landing slots at congested airports if they do not...
Wells Fargo Unusual Options Activity For April 10
Wells Fargo Unusual Options Activity For April 10
Apr 10, 2024
Deep-pocketed investors have adopted a bullish approach towards Wells Fargo ( WFC ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WFC usually suggests something big is about to happen. We gleaned this information...
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Apr 10, 2024
Alpine Immune Sciences Inc ( ALPN ) is reportedly considering strategic options, including a potential sale, following interest from potential buyers.  The Seattle-based firm is working closely with advisors and evaluating various possibilities, and at least one major pharmaceutical player has expressed interest in an acquisition. While discussions are ongoing, Bloomberg cautioned, citing sources familiar with the matter, that no decision has...
Copyright 2023-2026 - www.financetom.com All Rights Reserved